Device/Diagnostics Quarterly Deal Statistics, Q2 2015
A look at financing, M&A and alliance activity April–June 2015
Executive Summary
At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.
You may also be interested in...
Ophthalmology Surgeons, Companies Finding Solutions In Medtech
Minimally invasive technologies are finding their way into the suites of ophthalmology surgeons. Just over the past six months, Allergan has acquired two pre-commercial medtech companies developing miniature implants to treat glaucoma and dry eye disease. Meanwhile, Glaukos, a leader in the micro-invasive glaucoma surgery market, remains one of the more successful medtech IPOs.
US Neurostimulation Devices Market Forecast to Grow By $1B+ With New Indications, New Technologies
The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.
Newly Public Glaukos Unveils Vision For The MIGS Market
Glaukos held its first earnings call Aug. 12 following the completion of its $113 million IPO, which closed in June. The firm is the first to the U.S. market with a micro-invasive glaucoma surgery, or MIGS, device and it is working to get its next-generation system that can be performed separate from cataract surgery to market in the coming years.